Skip Navigation

European Heart Journal 1990 11(Supplement B):94-99; doi:10.1093/eurheartj/11.suppl_B.94
Copyright © 1990 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Mehta, P. M.
Right arrow Articles by Kloner, R. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mehta, P. M.
Right arrow Articles by Kloner, R. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1990 The European Society of Cardiology

Cardioprotective effects of captopril in myocardial ischaemia, ischaemia/reperfusion and infarction

P. M. Mehta*, K. Przyklenk{dagger} and R. A. Kloner{dagger},||,

* Wayne State University and Harper Hospital, Cardiology Division Detroit, MI
{dagger} The Heart Institute of the Hospital of the Good Samaritan Los Angeles, CA
|| University of Southern California, Section of Cardiology Los Angeles, CA, U.S.A.

Reprint requests to: Robert A. Kloner MD, PhD, Director of Research, The Heart Institute, The Hospital of the Good Samaritan, 616 South Witmer Street, Los Angeles, California 90017, U.S.A.

Several experimental studies have suggested that the sulphydryl-containing angiotensin-converting enzyme inhibitor, captopril, has cardioprotective effects in the setting of acute myocardial ischaemia, ischaemia/reperfusion and infarction. We have observed that captopril can reduce the degree of dilatation and early functional myocardial infarct expansion produced by 3 h of permanent coronary artery occlusion in anaesthetized, open-chest dogs. In addition, captopril has been shown to limit experimental infarct size, reduce the incidence of reperfusion arrhythmias, and improve contractile function of stunned myocardium. When administered chronically after myocardial infarction, both experimental and clinical evidence suggests that captopril reduces left ventricular dilatation. Captopril is currently being tested in large clinical trials as adjuvant therapy to thrombolysis.

Key Words: Captopril • angiotensin converting enzyme inhibitor • myocardial infarct expansion • myocardial infarction • myocardial ischaemia • oxygen free radicals


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.